Preclinical Efficacy Evaluation of Agonistic CD137 Therapeutic Antibodies in Human CD137 Knock-In Mouse Models (HuGEMM™)
Xuesong Huang, Gang Chen*, Lei Zheng, Annie An, Jean-Pierre Wery, Jay Liu*, Xin Dong*, Qian Shi, and Davy Xuesong Ouyang
*Nanjing Galaxy Biopharmaceutical Co. Ltd., Nanjing, China
Despite the huge clinical success of PD-1/PD-L1 checkpoint inhibitors in multiple tumor types, overall response rate to these agents is still low.
Growing efforts are focusing on priming and activating T cells through agonistic CD137 antibodies as combinatory strategies to improve tumor killing activities of T cells.
Multiple agonistic CD137 antibodies and PD-L1/CD137 bi-specific antibodies are currently under development; however, a lack of preclinical animal models for in vivo efficacy testing of these human-specific therapeutic antibodies has hindered the research process.
Read this Poster to Discover:
- The creation of a CD137 humanized model for evaluating CD137 mAb therapeutic efficacy
- That MC38 tumors engrafted in these models respond to anti-CD137 antibody treatment, and combination therapy with CD137 + PD-1/PD-L1 antibodies
- A range of preclinical target humanized models, including PD-1, CTLA-4, and OX40, used to assess immuno-oncology mAb therapeutic efficacy